Preclinical studies suggest that targeting the PI3K-Akt pathway inhibits clear cell carcinoma tumor growth in a mouse model and that loss of ARID1A further sensitizes cells to PI3K- and Akt-inhibition [133,134]. Here, ARID1A is linked to clear cell adenocarcinoma.